Raymond James Trust’s ADMA Biologics ADMA Stock Holding History

Raymond James Trust’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-17,792	Closed	-$80K	–	892
2018 Q2	$80K	Buy	+17,792	New	+$88.7K	﹤0.01%	851

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

Raymond James Trust's ADMA Position: Q3 2018 in Review

Raymond James Trust sold out of ADMA Biologics (ADMA) in Q3 2018, closing a stake of 17,792 shares — an estimated $80K sold.

Raymond James Trust first reported a position in ADMA in Q2 2018 and held it in 1 quarter. The position peaked at $80K in Q2 2018. 58 funds tracked by Wall St. Rank hold ADMA as of Q3 2018.

Raymond James Trust reported no remaining ADMA Biologics position as of Q3 2018 after selling out during the quarter.
Raymond James Trust sold 17,792 ADMA Biologics shares in Q3 2018, an estimated $80K.
Raymond James Trust first reported a position in ADMA Biologics in Q2 2018 and held it in 1 quarter.
Raymond James Trust's ADMA Biologics position peaked at $80K in Q2 2018.
58 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2018.

Based on Raymond James Trust's 13F filing for Q3 2018, filed 16 Oct 2018.